Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections

Entering the era of highly effective modulator therapies

(2021) Kavita Dave et al.   PEDIATRIC PULMONOLOGY

Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor

(2021) Gisli G. Einarsson et al.   Journal of Cystic Fibrosis

Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry

(2021) Christopher R. Kawala et al.   Journal of Cystic Fibrosis

Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome

(2020) Maria T Nelson et al.   THORAX

Polyclonality, Shared Strains, and Convergent Evolution in Chronic CF S. aureus Airway Infection

(2020) Dustin R Long et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor

(2019) Sachinkumar B. Singh et al.   PEDIATRIC PULMONOLOGY

Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis

(2019) Peter Jorth et al.   Cell Reports

Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics—A Novel Way to Combat Antibiotic Resistance?

(2019) Maria S. Zharkova et al.   Frontiers in Cellular and Infection Microbiology

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

(2019) Nataliya Volkova et al.   Journal of Cystic Fibrosis

Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy

(2019) Lisa Saiman   PEDIATRIC PULMONOLOGY

The Staphylococcus aureus Transcriptome during Cystic Fibrosis Lung Infection

(2019) Carolyn B. Ibberson et al.   mBio

Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis

(2018) Jordana E. Hoppe et al.   Journal of Cystic Fibrosis

High-resolution in situ transcriptomics of Pseudomonas aeruginosa unveils genotype independent patho-phenotypes in cystic fibrosis lungs

(2018) Elio Rossi et al.   Nature Communications

Pseudomonas aeruginosa in Chronic Lung Infections: How to Adapt Within the Host?

(2018) Emmanuel Faure et al.   Frontiers in Immunology

Molecular mechanisms of innate memory and tolerance to LPS

(2016) John J. Seeley et al.   JOURNAL OF LEUKOCYTE BIOLOGY

DADA2: High-resolution sample inference from Illumina amplicon data

(2016) Benjamin J Callahan et al.   NATURE METHODS

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response

(2015) John C Lam et al.   BMC INFECTIOUS DISEASES

Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs

(2015) Peter Jorth et al.   Cell Host & Microbe

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

(2015) J. Stuart Elborn et al.   Journal of Cystic Fibrosis

Trace incorporation of heavy water reveals slow and heterogeneous pathogen growth rates in cystic fibrosis sputum

(2015) Sebastian H. Kopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection

(2015) Sophie E. Darch et al.   Scientific Reports

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

(2015) Richard B Moss et al.   Lancet Respiratory Medicine

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

(2014) Steven M. Rowe et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

(2014) Sonya L. Heltshe et al.   CLINICAL INFECTIOUS DISEASES

Polymorphonuclear Leukocytes Restrict Growth of Pseudomonas aeruginosa in the Lungs of Cystic Fibrosis Patients

(2014) Kasper N. Kragh et al.   INFECTION AND IMMUNITY

Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis

(2013) Abdul Ashish et al.   Journal of Cystic Fibrosis

Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures

(2013) Tami D Lieberman et al.   NATURE GENETICS

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

(2012) Philip H. Quanjer et al.   EUROPEAN RESPIRATORY JOURNAL

Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung

(2012) Alejandro A. Pezzulo et al.   NATURE

Fundamentals of Microbial Community Resistance and Resilience

(2012) Ashley Shade et al.   Frontiers in Microbiology

A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation

(2011) Bonnie W. Ramsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolutionary dynamics of bacteria in a human host environment

(2011) L. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanical robustness of Pseudomonasaeruginosa biofilms

(2011) Oliver Lieleg et al.   Soft Matter

Pseudomonas Aeruginosa: Resistance to the Max

(2011) Keith Poole   Frontiers in Microbiology

Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method

(2010) Hoang Vu-Thien et al.   BMC MICROBIOLOGY

Pseudomonas aeruginosa Evasion of Phagocytosis Is Mediated by Loss of Swimming Motility and Is Independent of Flagellum Expression

(2010) E. Amiel et al.   INFECTION AND IMMUNITY

Functional relationship between bacterial cell density and the efficacy of antibiotics

(2009) K. I. Udekwu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY